Efficacy of growth factors compared to other therapies for low‐risk myelodysplastic syndromes

The myelodysplastic syndromes (MDS) represent a heterogeneous group of disorders. Low‐risk MDS represent a subgroup with a relatively good prognosis, but with few trials evaluating outcomes. A pooled analysis based upon a MEDLINE search identified 162 original articles describing patient characteristics and effect of therapy on 2592 individuals with pathologically confirmed refractory anaemia or refractory anaemia with ringed sideroblasts with <5% bone marrow blasts. Treatments were categorised as growth factors (GF) or non‐growth factors (NGF). International Prognostic Scoring System (IPSS) score was documented or calculated when possible. Responses and outcomes were standardised according to the International Working Group MDS criteria. Growth factors produced higher overall response rates (39·5% vs. 31·4% for NGF, P = 0·019), while NGF yielded better CR/PR rates (25·6% vs. 9·1% for GF, P = 0·03). Over 2 years of follow‐up, those receiving GF demonstrated greater overall and progression‐free survival than NGF, after controlling for baseline patient characteristics. Decision tools need to be developed to determine which therapy to choose for patients with low‐risk MDS.

[1]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[2]  R. Larson.  Myelodysplasia: when to treat and how. , 2006, Best practice & research. Clinical haematology.

[3]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  I. Dybedal,et al.  Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. , 2005, Blood.

[5]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[6]  G. Mufti,et al.  Thalidomide therapy for low-risk Myelodysplasia. , 2005, Leukemia research.

[7]  J. Winter,et al.  The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study , 2005, Annals of Hematology.

[8]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[9]  H. Dombret,et al.  Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. , 2004, Blood.

[10]  John P Klein,et al.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.

[11]  Robert B Howe,et al.  The WHO classification of MDS does make a difference. , 2004, Blood.

[12]  H. Heimpel,et al.  A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.

[13]  M. Tomonaga,et al.  Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. , 2003, Leukemia research.

[14]  A. la Sala,et al.  Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes , 2003, British journal of haematology.

[15]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[16]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[17]  Nikolaos Laoutaris,et al.  Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients , 2002, British journal of haematology.

[18]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Nordahl,et al.  Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes , 2002, European journal of haematology.

[20]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.

[21]  U. Germing,et al.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.

[22]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[23]  V. Diehl,et al.  Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony‐stimulating factor and erythropoietin , 2000, British journal of haematology.

[24]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  N. Piva,et al.  A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes , 1998, British journal of haematology.

[26]  I. Dybedal,et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. , 1998, Blood.

[27]  K. Miller.  Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. , 1998, Leukemia research.

[28]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[29]  P. Greenberg,et al.  Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. , 1996, Blood.

[30]  E. Hellström-Lindberg.  Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies , 1995, British journal of haematology.

[31]  M. Mittelman,et al.  Clinical application of recombinant erythropoietin in myelodysplasia. , 1994, Hematology/oncology clinics of North America.

[32]  D. Heitjan,et al.  Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. , 1988, Blood.

[33]  R. Clark,et al.  EFFECT OF 13-cis-RETINOIC ACID ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME , 1987, The Lancet.

[34]  J. Armitage,et al.  Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases , 1985, Cancer.

[35]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.